Answers are grounded in this paper and cite their sources.
Experiments show lacidipine reduces inflammatory markers and boosts cytotoxicity in SW480 cells, suggesting anticancer potential.
Objective: This study aimed to evaluate the antiproliferative effects of lacidipine, a dihydropyridine-derived L-type calcium channel blocker, on the human colon cancer cell line (SW480) and the associated changes in inflammatory and oxidative stress markers. Materials and Methods: SW480 cells were exposed to lacidipine doses ranging from 100 to 250 µg/mL. Cytotoxicity was assessed using the MTT assay. Oxidative stress levels were measured using TAC and TOS parameters, while the inflammatory response was assessed using ELISA for IL-1β, TNF-α, and TGF-β levels. Results: Lacidipine exhibited significant cytotoxic effects at a dose of 100 µg/mL, but increased cell viability was observed at higher doses. No statistically significant changes were observed in TAC and TOS levels. However, a significant decrease in IL-1β, TNF-α, and TGF-β levels was detected due to lacidipine; the most effective dose was determined to be 150 µg/mL. Conclusion: Lacidipine may have an antiproliferative effect by reducing inflammatory cytokine levels in SW480 colon cancer cells. These findings support the potential anticancer effect of lacidipine related to its anti-inflammatory properties, and further preclinical studies are needed to elucidate its mechanisms.
No takes yet. Share an insight, caveat, or question.
Balpınar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: